News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,895 Results
Type
Article (39144)
Company Profile (283)
Press Release (648468)
Section
Business (203900)
Career Advice (1996)
Deals (35371)
Drug Delivery (89)
Drug Development (80846)
Employer Resources (168)
FDA (16098)
Job Trends (14808)
News (344638)
Policy (32450)
Tag
Academia (2530)
Alliances (49183)
Alzheimer's disease (1257)
Approvals (16049)
Artificial intelligence (144)
Bankruptcy (352)
Best Places to Work (11581)
Biotechnology (200)
Breast cancer (188)
Cancer (1365)
Cardiovascular disease (110)
Career advice (1664)
Cell therapy (281)
Clinical research (64692)
Collaboration (482)
Compensation (260)
COVID-19 (2541)
C-suite (108)
Data (1389)
Diabetes (172)
Diagnostics (6170)
Earnings (84892)
Employer resources (146)
Events (110005)
Executive appointments (394)
FDA (16767)
Funding (426)
Gene therapy (195)
GLP-1 (597)
Government (4333)
Healthcare (18693)
Infectious disease (2633)
Inflammatory bowel disease (111)
Interviews (309)
IPO (16339)
Job creations (3625)
Job search strategy (1418)
Layoffs (418)
Legal (7861)
Lung cancer (197)
Lymphoma (98)
Manufacturing (206)
Medical device (13211)
Medtech (13216)
Mergers & acquisitions (19192)
Metabolic disorders (452)
Neuroscience (1577)
NextGen Class of 2024 (6500)
Non-profit (4467)
Northern California (1693)
Obesity (258)
Opinion (183)
Patents (117)
People (56455)
Phase I (20119)
Phase II (28493)
Phase III (21237)
Pipeline (514)
Postmarket research (2560)
Preclinical (8545)
Radiopharmaceuticals (236)
Rare diseases (259)
Real estate (5890)
Regulatory (21664)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1460)
Startups (3562)
United States (15141)
Vaccines (563)
Weight loss (181)
Date
Last 7 days (580)
Last 30 days (2251)
Last 365 days (35161)
2024 (35002)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54086)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31319)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (195)
Asia (37266)
Australia (6087)
California (3809)
Canada (1449)
China (304)
Colorado (171)
Connecticut (176)
Europe (79825)
Florida (533)
Georgia (135)
Illinois (384)
Indiana (224)
Maryland (626)
Massachusetts (2959)
Michigan (172)
Minnesota (290)
New Jersey (1100)
New York (1080)
North Carolina (742)
Northern California (1693)
Ohio (146)
Pennsylvania (923)
South America (1091)
Southern California (1460)
Texas (547)
Utah (108)
Washington State (399)
687,895 Results for "psychogenics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
PsychoGenics Awarded an NIH Contract to Test and Identify Novel Therapeutics for Pain
October 8, 2024
·
2 min read
Pharm Country
PsychoGenics Launches an Updated Corporate Identity and Brand
PsychoGenics Inc., the leading contract research organization specializing in central nervous system focused preclinical and translational drug discovery services, is proud to unveil its refreshed corporate identity and brand.
November 10, 2023
·
2 min read
Pharm Country
PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders
PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997. RO7117997, is an IND-ready Equilibrative Nucleoside Transporter 1 (ENT1) inhibitor discovered in partnership with Roche using the PsychoGenics’ AI-enabled phenotypic screening platforms.
December 1, 2023
·
3 min read
Pharm Country
PsychoGenics and Collaborations Pharmaceuticals awarded a $1M grant to use AI platforms to design new drugs for mental health disorders
PsychoGenics Inc. and Collaborations Pharmaceuticals, Inc. are pleased to announce that they were awarded a $1million Phase I Small Business Innovation Research grant, to use their combined AI tools to design new drugs for mental health disorders.
September 5, 2023
·
4 min read
Business
IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome
IAMA Therapeutics and PsychoGenics Inc. today announced that the companies have entered into an additional services agreement to identify the efficacy of novel drug candidates in preclinical animal models of Dravet syndrome.
January 12, 2023
·
3 min read
Business
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage biopharmaceutical company Karuna Therapeutics, Inc., (NASDAQ: KRTX) has extended its drug discovery collaboration with the Company aimed at identifying potential novel drug candidates for the treatment of severe neuropsychiatric disorders.
October 11, 2022
·
3 min read
Pharm Country
PsychoGenics’ High Data Security Standards Are Certified by The NIH
PsychoGenics Inc. announced that the National Institutes of Health (NIH) has completed the assessment of PsychoGenics data/IT security standards and systems, and gave official authority to operate as a government contractor.
January 12, 2022
·
2 min read
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Press Releases
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.
December 20, 2024
·
2 min read
Business
IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics
IAMA Therapeutics and PsychoGenics Inc., a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that the companies have entered into a service agreement to identify the efficacy of novel drug candidates in drug-resistant epilepsy.
July 25, 2022
·
3 min read
1 of 68,790
Next